These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Some healthy skepticism about inhaled therapy for tuberculosis. Iseman MD Clin Infect Dis; 2001 Jul; 33(2):266-7. PubMed ID: 11418891 [No Abstract] [Full Text] [Related]
3. [Relationship between the susceptibility testing of Mycobacterium avium complex strains and the clinical efficacy of antituberculosis drugs--an evidence suggesting that antituberculosis drugs are effective in the treatment of M. avium complex pulmonary infection]. Tsukamura M; Ichiyama S; Miyachi T Kekkaku; 1988 Apr; 63(4):227-31. PubMed ID: 3404801 [No Abstract] [Full Text] [Related]
4. [Experimental tuberculosis in mice, a model for the study of antitubercular chemotherapy]. Rist N Arch Roum Pathol Exp Microbiol; 1971 Jun; 30(2):295-6. PubMed ID: 5004388 [No Abstract] [Full Text] [Related]
5. [Possibility of the intensification of tuberculosis chemotherapy and its limits]. Naito M; Kanai K; Kondo E; Yamashita H; Matsui K Kekkaku; 1969 Nov; 44(11):377-93. PubMed ID: 4982567 [No Abstract] [Full Text] [Related]
6. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635 [TBL] [Abstract][Full Text] [Related]
7. [The bacteriology of tuberculosis and non-tuberculosis mycobacterial infections]. Wyplosz B; Truffot-Pernot C; Robert J; Jarlier V; Grosset J Rev Mal Respir; 1997 Dec; 14 Suppl 5():S33-48. PubMed ID: 9496590 [TBL] [Abstract][Full Text] [Related]
8. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Heifets LB; Iseman MD Am Rev Respir Dis; 1991 Jul; 144(1):1-2. PubMed ID: 2064112 [No Abstract] [Full Text] [Related]
14. [Research on primary resistance to antitubercular agents and antibiotics in the antituberculosis centers]. Santi GM; Poggiopollini M Minerva Med; 1967 Jun; 58(49):2285-8. PubMed ID: 6029301 [No Abstract] [Full Text] [Related]
15. [Clinical study on tuberactinomycin, a new antibiotic]. Osato T; Toyoara M Kekkaku; 1971 May; 46(3):59-63. PubMed ID: 4324041 [No Abstract] [Full Text] [Related]
16. Rifampicin and ethambutol in the treatment of drug resistant and far advanced pulmonary tuberculosis (with a note on capreomycin). Pines A; Raafat H; Siddiqui GM J Ir Med Assoc; 1970 Mar; 63(393):82-5. PubMed ID: 4984340 [No Abstract] [Full Text] [Related]
18. Studies on the open negative syndrome resulting from chemotherapy with secondary anti-tuberculosis agents. Kimura Y Jpn J Tuberc; 1966 Dec; 13():Suppl:71-6. PubMed ID: 5298482 [No Abstract] [Full Text] [Related]
19. Capreomycin and other drugs in the treatment of pulmonary tuberculosis. Zierski M Tubercle; 1969 Mar; 50():Suppl:37-9. PubMed ID: 4319132 [No Abstract] [Full Text] [Related]
20. [Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones]. Tomioka H; Sato K; Saito H Kekkaku; 1996 Sep; 71(9):531-5. PubMed ID: 8999135 [No Abstract] [Full Text] [Related] [Next] [New Search]